FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3103572421> ?p ?o ?g. }

• W3103572421 endingPage "1744" @default.
• W3103572421 startingPage "1737" @default.
• W3103572421 abstract "Background Percutaneous coronary intervention (PCI)-related myonecrosis is frequent and can affect the long-term prognosis of patients. To our knowledge, ticagrelor has not been evaluated in elective PCI and could reduce periprocedural ischaemic complications compared with clopidogrel, the currently recommended treatment. The aim of the ALPHEUS study was to examine if ticagrelor was superior to clopidogrel in reducing periprocedural myocardial necrosis in stable coronary patients undergoing high-risk elective PCI. Methods The ALPHEUS study, a phase 3b, randomised, open-label trial, was done at 49 hospitals in France and Czech Republic. Patients with stable coronary artery disease were eligible for the study if they had an indication for PCI and at least one high-risk characteristic. Eligible patients were randomly assigned (1:1) to either ticagrelor (180 mg loading dose, 90 mg twice daily thereafter for 30 days) or clopidogrel (300–600 mg loading dose, 75 mg daily thereafter for 30 days) by use of an interactive web response system, and stratified by centre. The primary outcome was a composite of PCI-related type 4 (a or b) myocardial infarction or major myocardial injury and the primary safety outcome was major bleeding, both of which were evaluated within 48 h of PCI (or at hospital discharge if earlier). The primary analysis was based on all events that occurred in the intention-to-treat population. The trial was registered with ClinicalTrials.gov, NCT02617290. Findings Between Jan 9, 2017, and May 28, 2020, 1910 patients were randomly assigned at 49 sites, 956 to the ticagrelor group and 954 to the clopidogrel group. 15 patients were excluded from the ticagrelor group and 12 from the clopidogrel group. At 48 h, the primary outcome was observed in 334 (35%) of 941 patients in the ticagrelor group and 341 (36%) of 942 patients in the clopidogrel group (odds ratio [OR] 0·97, 95% CI 0·80–1·17; p=0·75). The primary safety outcome did not differ between the two groups, but minor bleeding events were more frequently observed with ticagrelor than clopidogrel at 30 days (105 [11%] of 941 patients in the ticagrelor group vs 71 [8%] of 942 patients in the clopidogrel group; OR 1·54, 95% CI 1·12–2·11; p=0·0070). Interpretation Ticagrelor was not superior to clopidogrel in reducing periprocedural myocardial necrosis after elective PCI and did not cause an increase in major bleeding, but did increase the rate of minor bleeding at 30 days. These results support the use of clopidogrel as the standard of care for elective PCI. Funding ACTION Study Group and AstraZeneca." @default.
• W3103572421 created "2020-11-23" @default.
• W3103572421 creator A5000595044 @default.
• W3103572421 creator A5000882502 @default.
• W3103572421 creator A5001099577 @default.
• W3103572421 creator A5001241536 @default.
• W3103572421 creator A5001725935 @default.
• W3103572421 creator A5001874109 @default.
• W3103572421 creator A5002442538 @default.
• W3103572421 creator A5002901473 @default.
• W3103572421 creator A5003014889 @default.
• W3103572421 creator A5003853117 @default.
• W3103572421 creator A5003895442 @default.
• W3103572421 creator A5003939931 @default.
• W3103572421 creator A5004320719 @default.
• W3103572421 creator A5004730228 @default.
• W3103572421 creator A5005074733 @default.
• W3103572421 creator A5006980808 @default.
• W3103572421 creator A5008202788 @default.
• W3103572421 creator A5009593325 @default.
• W3103572421 creator A5009784084 @default.
• W3103572421 creator A5010572278 @default.
• W3103572421 creator A5011483368 @default.
• W3103572421 creator A5011661175 @default.
• W3103572421 creator A5011778773 @default.
• W3103572421 creator A5012847381 @default.
• W3103572421 creator A5013118876 @default.
• W3103572421 creator A5013147380 @default.
• W3103572421 creator A5013439193 @default.
• W3103572421 creator A5013774583 @default.
• W3103572421 creator A5014289806 @default.
• W3103572421 creator A5014713758 @default.
• W3103572421 creator A5014948738 @default.
• W3103572421 creator A5015350171 @default.
• W3103572421 creator A5015921253 @default.
• W3103572421 creator A5016160566 @default.
• W3103572421 creator A5016593269 @default.
• W3103572421 creator A5017286905 @default.
• W3103572421 creator A5017709997 @default.
• W3103572421 creator A5017751943 @default.
• W3103572421 creator A5018045771 @default.
• W3103572421 creator A5018110974 @default.
• W3103572421 creator A5018386256 @default.
• W3103572421 creator A5020632209 @default.
• W3103572421 creator A5021221153 @default.
• W3103572421 creator A5021546759 @default.
• W3103572421 creator A5021599674 @default.
• W3103572421 creator A5021936320 @default.
• W3103572421 creator A5022057350 @default.
• W3103572421 creator A5022468544 @default.
• W3103572421 creator A5022764474 @default.
• W3103572421 creator A5022935861 @default.
• W3103572421 creator A5023214189 @default.
• W3103572421 creator A5023428783 @default.
• W3103572421 creator A5023572557 @default.
• W3103572421 creator A5024302369 @default.
• W3103572421 creator A5024424811 @default.
• W3103572421 creator A5025777104 @default.
• W3103572421 creator A5026274111 @default.
• W3103572421 creator A5027244910 @default.
• W3103572421 creator A5028288641 @default.
• W3103572421 creator A5029066902 @default.
• W3103572421 creator A5029132663 @default.
• W3103572421 creator A5030249150 @default.
• W3103572421 creator A5030620867 @default.
• W3103572421 creator A5031127483 @default.
• W3103572421 creator A5031251580 @default.
• W3103572421 creator A5031293394 @default.
• W3103572421 creator A5032143477 @default.
• W3103572421 creator A5032224302 @default.
• W3103572421 creator A5032245948 @default.
• W3103572421 creator A5033294194 @default.
• W3103572421 creator A5033620945 @default.
• W3103572421 creator A5033762387 @default.
• W3103572421 creator A5033866835 @default.
• W3103572421 creator A5035015657 @default.
• W3103572421 creator A5036264641 @default.
• W3103572421 creator A5037198906 @default.
• W3103572421 creator A5037312839 @default.
• W3103572421 creator A5037319937 @default.
• W3103572421 creator A5037640995 @default.
• W3103572421 creator A5038511231 @default.
• W3103572421 creator A5039098596 @default.
• W3103572421 creator A5039443605 @default.
• W3103572421 creator A5040563995 @default.
• W3103572421 creator A5040636188 @default.
• W3103572421 creator A5041581745 @default.
• W3103572421 creator A5041649512 @default.
• W3103572421 creator A5041722817 @default.
• W3103572421 creator A5042219174 @default.
• W3103572421 creator A5042554656 @default.
• W3103572421 creator A5042959417 @default.
• W3103572421 creator A5043059347 @default.
• W3103572421 creator A5043561301 @default.
• W3103572421 creator A5043565272 @default.
• W3103572421 creator A5044604637 @default.
• W3103572421 creator A5044692014 @default.
• W3103572421 creator A5045082140 @default.

• next